Compugen (CGEN) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Compugen (CGEN) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 22.2% versus a loss of 51.6%. Over five years, CGEN leads with a -66.2% price change compared with -96.8% for LYEL. Lyell Immunopharma is the larger company by market cap ($206.1 million vs $195.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEN | LYEL |
|---|---|---|
| Share price | $2.07 | $8.41 |
| Market cap | $195.61M | $206.09M |
| 1-day change | -3.95% | -1.75% |
| YTD return | +40.52% | -72.19% |
| 1-year return | +22.16% | -51.61% |
| 5-year return | -66.19% | -96.78% |
| P/E ratio (TTM) | 5.43 | — |
| EPS (TTM) | $0.38 | $-12.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.24 | $45.00 |
| 52-week low | $1.43 | $8.21 |
| Distance from 52-week high | -36.27% | -81.31% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +122.76% | +350.42% |
| Average volume | 247.05K | 144.81K |
| Shares outstanding | 94.72M | 24.51M |
| Employees | 75 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEN has outperformed LYEL by 73.8 percentage points over the past year.
About Compugen
CGEN stock →Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
CGEN vs LYEL FAQ
Which is bigger, Compugen or Lyell Immunopharma?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $206.09M compared with $195.61M for Compugen (CGEN).
Which stock has performed better over the past year, CGEN or LYEL?
CGEN returned +22.16% over the past 12 months, compared with -51.61% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Compugen and Lyell Immunopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Compugen and Biotechnology: Pharmaceutical Preparations for Lyell Immunopharma.